Enveric Biosciences, Inc.
ENVB· Nasdaq
Filed Aug 14, 2025 · 10-Q · 45 days after period end · 0001641172-25-024021
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Net Income | -$2.52M | -$1.88M | -$6.36M | -$2.79M |
| EPS Diluted | -$11.65 | -$3.72 | -$3.04 | -$2.73 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
ended Jun 30, 2025 · filed Aug 14, 2025 · 45 d after period end